2025
Predictive and monitoring value of blood‐based biomarkers for apathy treatment in Alzheimer’s disease
Lanctôt K, Tumati S, Vieira D, Bawa K, Andreazza A, Scherer R, Rosenberg P, van Dyck C, Padala P, Brawman‐Mintzer O, Porsteinsson A, Lerner A, Craft S, Levey A, Burke W, Perin J, Shade D, Mintzer J, Herrmann N. Predictive and monitoring value of blood‐based biomarkers for apathy treatment in Alzheimer’s disease. Alzheimer's & Dementia 2025, 20: e095596. PMCID: PMC11712725, DOI: 10.1002/alz.095596.Peer-Reviewed Original ResearchTreatment responseBlood-based biomarkersBlood-based biomarkers of neurodegenerationNPI-aClinical predictorsAlzheimer's diseaseClinical predictors of responsePredictive value of biomarkersTumor necrosis factor-alphaOxidative stressNeurofilament lightAffecting treatment responsePredictors of responseNecrosis factor-alphaBiomarkers of neurodegenerationInterleukin (IL)-6Treatment response predictionMonths end pointAssociated with apathyValue of biomarkersNeuropsychiatric Inventory apathy subscalePresence of anxietyPeripheral inflammation
2022
Performance of a fully-automated Lumipulse plasma phospho-tau181 assay for Alzheimer’s disease
Wilson E, Young C, Ramos Benitez J, Swarovski M, Feinstein I, Vandijck M, Le Guen Y, Kasireddy N, Shahid M, Corso N, Wang Q, Kennedy G, Trelle A, Lind B, Channappa D, Belnap M, Ramirez V, Skylar-Scott I, Younes K, Yutsis M, Le Bastard N, Quinn J, van Dyck C, Nairn A, Fredericks C, Tian L, Kerchner G, Montine T, Sha S, Davidzon G, Henderson V, Longo F, Greicius M, Wagner A, Wyss-Coray T, Poston K, Mormino E, Andreasson K. Performance of a fully-automated Lumipulse plasma phospho-tau181 assay for Alzheimer’s disease. Alzheimer's Research & Therapy 2022, 14: 172. PMID: 36371232, PMCID: PMC9652927, DOI: 10.1186/s13195-022-01116-2.Peer-Reviewed Original ResearchConceptsPlasma p-tau181Alzheimer's Disease Research CenterP-tau181Disease Research CenterAlzheimer's diseasePositron emission tomographyAD dementiaBlood-based biomarker assaysAmyloid positron emission tomographyTreatment monitoringNovel blood-based biomarkersCSF p-tau181P-tau181 concentrationsDisease-modifying therapiesAβ42/Aβ40 ratioBlood-based biomarkersClinical AD diagnosisDetection of ADMild cognitive impairmentStudy cohortCSF biomarkersPlasma levelsAD groupPrognostic performanceCDR sum
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply